[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406247-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406247-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-in-prostate-cancer-treatment-with-moderate-and-ultrahypofractionated-radiotherapy-minireviews","Advances in prostate cancer treatment with moderate and ultrahypofractionated radiotherapy - Minireviews","","This minireview comprehensively reviews research progress in prostate cancer radiation therapy, outlining epidemiology, pathological mechanisms, and radiation sensitivity while summarizing key technological advances. It discusses clinical use, technical development, and efficacy evaluation for moderate hypofractionated and ultra hypofractionated radiotherapy, including radiation-therapy–specific diagnostics and monitoring. Prevailing controversies and practical challenges are analyzed, and future prospects highlight emerging techniques, multidisciplinary collaboration trends, and radiation’s evolving role in comprehensive care, emphasizing ongoing need to optimize regimens to improve survival and quality of life.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-prostate-cancer-treatment-with-moderate-and-ultrahypofractionated-radiotherapy-minireviews/406247/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-prostate-cancer-treatment-with-moderate-and-ultrahypofractionated-radiotherapy-minireviews/406247.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this minireview?","Question",{"text":63,"@type":64},"It reviews advances in prostate cancer radiation therapy, emphasizing moderate hypofractionated and ultra hypofractionated radiotherapy. The review also covers diagnostics/monitoring, controversies, challenges, and future directions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatment regimens are compared or evaluated?",{"text":68,"@type":64},"The article discusses clinical application, technology progress, and efficacy evaluation of moderate hypofractionated radiation therapy (MHRT) and ultra hypofractionated radiation therapy (UHRT).",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges and future prospects are highlighted?",{"text":72,"@type":64},"Key challenges include acute and late toxicities, optimal patient selection, and integrating advanced imaging or biomarker guidance. Future prospects include novel radiotherapy techniques (e.g., FLASH and proton therapy) and increasing multidisciplinary collaboration to improve survival and quality of life.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406247,1790912926,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","| W | J | C | O | World Journal of\u003Cbr>Clinical Oncology |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Clin Oncol 2025 December 24; 16(12): 112735  \nDOI: 10.5306/wjco.v16.i12.112735 ISSN 2218-4333 (online)  \nMINIREVIEWS  \nAdvances in prostate cancer treatment with moderate and ultrahypofractionated radiotherapy  \nLing-Ling Meng, Yu-Peng Di, Lin Ma, Bao-Lin Qu  \nSpecialty type: Oncology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B  \nNovelty: Grade B  \nCreativity or Innovation: Grade B  \nScientific Significance: Grade B  \nP-Reviewer: He MZ, PhD, Russia  \nReceived: August 5, 2025  \nRevised: September 15, 2025  \nAccepted: November 17, 2025  \nPublished online: December 24, 2025  \nProcessing time: 140 Days and 21.3 Hours  \nLing-Ling Meng, Lin Ma, Bao-Lin Qu, Department of Radiation Oncology, Senior Department of Oncology, The First Medical Center of PLA General Hospital, Beijing, 100853, China  \nYu-Peng Di, Department of Radiation Oncology, Air Force Medical Center, Air Force Medical University, Beijing 100142, China  \nCo-first authors: Ling-Ling Meng and Yu-Peng Di.  \nCo-corresponding authors: Lin Ma and Bao-Lin Qu.  \nCorresponding author: Bao-Lin Qu, MD, PhD, Professor, Department of Radiation Oncology, Senior Department of Oncology, The First Medical Center of PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, [China.](China. radiotherapy1018@126.com)[ radiotherapy1018@126.com](China. radiotherapy1018@126.com)  \nAbstract  \nThis article comprehensively reviews research progress in prostate cancer radiation therapy. It provides an overview of fundamental principles, encompassing the disease’s epidemiology, pathological mechanisms, and radiation sensitivity, alongside technological advancements. The clinical application, technological progress, and efficacy evaluation of moderate hypofractionated radiation therapy and ultra hypofractionated radiation therapy are discussed. Diagnostic and monitoring techniques specific to radiation therapy are analyzed, alongside prevailing controversies and challenges. Finally, the review outlines future prospects, including novel radiotherapy techniques, multidisciplinary collaboration trends, and the evolving role of radiation within comprehensive treatment. The findings demonstrate continuous technological and clinical evolution in prostate cancer radiotherapy, yet emphasize the need for further exploration to optimize treatments and improve patient survival and quality of life.  \nKey Words: Prostate cancer; Moderate; Ultra-hypofractionated; Radiation therapy; Treatment; Multidisciplinary collaboration  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJCO  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 24, 2025  Volume 16  Issue 12   \nMeng LL et al. Prostate cancer hypofractionation  \nCore Tip: Technological advances enabling precise targeting have driven continuous evolution in radiation therapy for prostate cancer. Moderate and ultra-hypofractionated regimens have been shown to be as effective as conventional therapy and offer patients greater convenience. However, optimizing treatment strategies requires overcoming challenges such as managing toxicity, defining the optimal dose/fractionation, integrating advanced diagnostics to enable personalized approaches and clarifying the role of radiation within multimodal management. Future progress hinges on refining novel techniques (e.g., FLASH and proton therapy), fostering multidisciplinary collaboration, and focusing on improving survival and quality of life outcomes for patients.  \nCitation: Meng LL, Di YP, Ma L, Qu BL. Advances in prostate cancer treatment with moderate and ultra-hypofractionated radiotherapy. World J Clin Oncol 2025; 16(12): 112735  \nURL: [https://www.wjgnet.co","cbCaieT3Rq6z8S1S","https://ap.wps.com/l/cbCaieT3Rq6z8S1S","pdf",1300589,13,"English","# Introduction\n## Epidemiologic features of prostate cancer\n# Core Tip\n## Technological advances and clinical evolution\n# Abstract\n## Principles, technologies, and clinical applications\n# Key Words\n## Moderate and ultra-hypofractionated regimens","[{\"question\":\"What is the main focus of this minireview?\",\"answer\":\"It reviews advances in prostate cancer radiation therapy, emphasizing moderate hypofractionated and ultra hypofractionated radiotherapy. The review also covers diagnostics/monitoring, controversies, challenges, and future directions.\"},{\"question\":\"Which treatment regimens are compared or evaluated?\",\"answer\":\"The article discusses clinical application, technology progress, and efficacy evaluation of moderate hypofractionated radiation therapy (MHRT) and ultra hypofractionated radiation therapy (UHRT).\"},{\"question\":\"What challenges and future prospects are highlighted?\",\"answer\":\"Key challenges include acute and late toxicities, optimal patient selection, and integrating advanced imaging or biomarker guidance. Future prospects include novel radiotherapy techniques (e.g., FLASH and proton therapy) and increasing multidisciplinary collaboration to improve survival and quality of life.\"}]","Advances in prostate cancer treatment with moderate and ultrahypofractionated radiotherapy - Minireviews | PDF",1790564392,33]